dromlakhani Gastrointestinal Symptom Management in PPGL Using Phentolamine and Metyrosine
STEP 1 — Gather Information
Collect history of bowel frequency, stool consistency, abdominal distension, pain, and presence of obstipation or ileus; assess vital signs, abdominal exam for tenderness or tympany; obtain plasma-free metanephrines or 24‑hour urinary fractionated catecholamines to confirm catecholamine excess; review medications (opioids, anticholinergics) that may contribute. If symptoms are present and catecholamine excess is suspected, proceed to rule in/out.
STEP 2 — Rule In / Rule Out
Rule out non‑catecholamine causes of GI dysmotility (e.g., opioid‑induced constipation, hypothyroidism, hypercalcemia, mechanical obstruction) versus rule in catecholamine‑mediated intestinal relaxation. If non‑catecholamine causes are excluded and biochemical evidence of catecholamine excess exists, proceed to classify severity.
STEP 3 — Classify or Stratify
Stratify GI symptom severity: mild (occasional constipation manageable with diet/lifestyle) versus moderate‑to‑severe (persistent constipation, obstipation, paralytic ileus, radiographic mega‑colon, or absent bowel sounds). If mild, consider conservative measures; if moderate‑to‑severe, proceed to decide on pharmacologic intervention.
STEP 4 — Decide
Administer intravenous phentolamine (e.g., 5 mg bolus followed by continuous infusion titrated to effect) and initiate oral metyrosine (starting dose 0.5 g/day, titrating up to 2–3 g/day as needed) to block α‑adrenergic receptors and inhibit catecholamine synthesis; monitor blood pressure for hypotension and GI symptoms for improvement; continue until bowel motility normalizes.
Clinical Guardrails / Mimics / Pitfalls
Do not use selective α‑blockers (e.g., doxazosin) as they are ineffective for catecholamine‑induced intestinal relaxation; avoid metoclopramide due to risk of hypertensive crisis in PPGL; monitor closely for hypotension during phentolamine infusion and adjust rate accordingly; do not delay treatment in suspected paralytic ileus as progression to perforation is possible; phenoxybenzamine is unavailable in Japan, so rely on phentolamine injectable formulations; metyrosine may cause drowsiness, insomnia, anxiety, or diarrhea — use caution in activities requiring alertness.
Concrete Clinical Example
A 48‑year‑old patient with known PPGL presents with 4 days of no bowel movements, abdominal distension, and mild tenderness. Labs show elevated plasma normetanephrine. Opioids and hypothyroidism are ruled out. Abdominal X‑ray reveals dilated colon suggestive of ileus. Treated with IV phentolamine 5 mg bolus then infusion at 0.1 mg/kg/h and oral metyrosine 0.5 g twice daily. Bowel movement occurs within 18 hours with symptom resolution.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI: 10.1507/endocrj.EJ25-0165